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ABSTRACT
Breast cancer initiation, progression and metastasis rely on a complex interplay 
between tumor cells and their surrounding microenvironment. Infiltrating immune 
cells, including macrophages, promote mammary tumor progression and metastasis; 
however, less is known about the role of macrophages in early stage lesions. In this 
study, we utilized a transplantable p53-null model of early progression to characterize 
the immune cell components of early stage lesions. We show that macrophages 
are recruited to ductal hyperplasias with a high tumor-forming potential where 
they are differentiated and polarized toward a tumor-promoting phenotype. These 
macrophages are a unique subset of macrophages, characterized by pro-inflammatory, 
anti-inflammatory and immunosuppressive factors. Macrophage ablation studies 
showed that macrophages are required for both early stage progression and primary 
tumor formation. These studies suggest that therapeutic targeting of tumor-promoting 
macrophages may not only be an effective strategy to block tumor progression and 
metastasis, but may also have critical implications for breast cancer prevention.
INTRODUCTION
Inflammation is a critical component of the tumor 
microenvironment that is required for tumor progression. 
While the immune system is a driving force against 
tumor initiation, anti-tumor immune responses may be 
subverted to allow for tumor formation and progression. 
Infiltrating inflammatory cells, including macrophages, 
promote tumor progression and metastasis in a number 
of cancers, such as prostate, bladder, colon and breast 
[1, 2]. Studies aimed at therapeutically targeting tumor-
driving components of the immune system are currently in 
progress and may be key to preventing cancer progression.
The tumor microenvironment plays a pivotal role 
in promoting breast cancer initiation, progression and 
metastasis. In particular, tumor-associated macrophages 
have been shown to promote breast cancer cell invasion 
and have been correlated with poor prognostic signs 
such as high tumor grade, low estrogen and progesterone 
status, high mitotic activity, and metastasis [3]. Although 
infiltrating macrophages were originally believed to 
exhibit anti-tumor activity, it is now well-established 
that once educated by the tumor microenvironment, 
macrophages secrete a number of factors to promote 
tumorigenesis. Numerous cell types influence macrophage 
function including the tumor cells themselves, which not 
only recruit macrophages to both primary and metastatic 
tumor sites by secreting chemokines such as CCL2, CCL5 
and CXCL12, but also differentiate and polarize them to a 
tumor-promoting phenotype [4].
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In mouse models of breast cancer, macrophages 
contribute to tumor progression through a variety of 
mechanisms including IL-10 and arginase 1 (Arg1)-mediated 
immunosuppression, MMP 7/9 and CCL18-induced matrix 
remodeling, and EGF and TNFα-stimulated tumor cell 
migration and metastasis [5–7]. These different functions are 
carried out by distinct macrophage subpopulations, reflecting 
the heterogeneity and plasticity that macrophages display in 
response to local cues. There are several markers that are 
commonly used to assess the phenotype of macrophages. The 
mannose receptor CD206, and the macrophage scavenger 
receptor CD204 are prototypic markers of anti-inflammatory 
macrophages and their expression negatively correlates with 
prognosis in numerous types of cancer. CD206 expression 
has been associated with increased MHCII expression and 
reduced pro-inflammatory cytokine secretion. Expression of 
CD204 by tumor-associated macrophages has been linked 
to suppression of anti-tumor immunity, the clearance of 
apoptotic cells, and tumor cell invasion and metastasis [8, 9].
Breast cancer is believed to arise in a stepwise 
fashion, beginning with atypical ductal hyperplasia (ADH), 
to ductal carcinoma in situ (DCIS), to invasive ductal 
carcinoma (IDC; primary tumor formation), and ultimately 
progressing to metastatic ductal carcinoma [10]. While it 
is well-established that macrophages are recruited to the 
invasive fronts of established tumors to promote angiogenesis 
and metastasis, fewer studies have focused on the role of 
macrophages in early stage lesions. One limitation in the 
field is the lack of in vivo models that recapitulate the early 
stages of ADH/DCIS progression. In this study, we utilized 
a transplantable p53-null mouse model to study factors 
that contribute to the progression of early stage mammary 
lesions [11]. Orthotopic transplantation of p53-/- mammary 
epithelial cells into wildtype mice led to the development 
of premalignant lesions that varied in breast cancer subtype, 
pathobiology, histology, and the ability to progress to 
invasive cancer. Two of these previously characterized lines, 
PN1a and PN1b, form estrogen and progesterone receptor 
positive ductal hyperplasias that are dependent on ovarian 
hormones for tumor formation and have been maintained 
by serial passaging in Balb/c mice [12]. Here, we show that 
macrophages are recruited to premalignant lesions with 
a high tumor-forming potential, where they are polarized 
toward a tumor-promoting subtype. In contrast, infiltrating 
macrophages were rarely found in lesions with a low tumor-
forming potential. The immune cell components of the 
pre-invasive lesions were characterized and suggested that 
as hyperplasias progress to invasive cancer, numerous anti-
inflammatory and immunosuppressive pathways are induced. 
Macrophage ablation studies showed that macrophages were 
required for early stage progression and primary tumor 
formation. These studies demonstrate that in this mouse 
model, recruited macrophages are instructed to differentiate 
into a tumor-promoting phenotype, which is crucial for 
the progression of early stage lesions. Understanding the 
molecular pathways that recruit and polarize macrophages 
will have critical implications for therapeutically blocking the 
tumor-promoting activities of macrophages.
RESULTS
Macrophages are recruited to early stage lesions
To investigate mechanisms that drive tumorigenesis 
in early breast cancer progression, we employed a 
transplantable model of early progression. As described 
previously [11], transplantation of p53-/- mammary 
epithelial cells into the cleared mammary fad pads of 
syngeneic wildtype mice led to the formation of several 
premalignant lines that histologically and genetically 
recapitulated the various subtypes of human breast cancer. 
Two of these lines, PN1a and PN1b, were derived from 
contralateral outgrowths from the same mouse, and tissue 
from these outgrowths was serially transplanted for over 
10 generations to confirm stability [11].
Examination of whole mounted PN1a and PN1b 
lesions shows that while both lesions exhibit a hyperplastic 
ductal morphology at 8 weeks post-transplantation, PN1a 
lesions progress to form nodules by 16 weeks (Figure 1A) 
[11]. Histological analysis shows that at 8 weeks post-
transplantation, both PN1a and PN1b lesions exhibit a 
well-differentiated ductal hyperplastic morphology. At 16 
weeks post-transplantation, PN1a lesions develop a poorly 
differentiated, lobuloalveolar morphology with multifocal 
regions of atypical cells in solid nests, while PN1b lesions 
remain low grade, ductal hyperplasia (Figure 1B). Previous 
studies demonstrated that PN1a lesions have a high tumor-
forming potential resulting in palpable tumors by 24 weeks. 
In contrast, ~15% of PN1b lesions progress to palpable 
tumors after 1 year (low tumor-forming potential) [11].
In order to identify genes important for the 
transition to invasive cancer, gene expression analysis was 
performed on PN1a and PN1b lesions at 8 weeks post-
transplantation. The results showed that approximately 
635 transcripts were differentially expressed (p<0.01 by 
t-test, fold change >1.5) in PN1a lesions as compared 
to PN1b (Figure 2A). Gene Ontology analysis revealed 
the alteration of genes associated with inflammation and 
innate immunity (Figure 2C). In support, a large cluster 
of immune cell-associated genes were significantly 
upregulated in PN1a as compared to PN1b and p53-/-  
lesions. These transcripts included several macrophage 
markers such as Ccr2, colony stimulating factor 1 receptor 
(Csf1r), Ccr5, Csf3r, and Cd68 (Figure 2B), suggesting 
an important role for macrophages in PN1a progression. 
To confirm theses results, immunohistochemistry 
was performed using an antibody to F4/80 to detect 
macrophages. There was a significant increase in 
infiltrating macrophages in PN1a lesions as compared to 
PN1b at 8 weeks post-transplantation, demonstrating their 
recruitment to ductal hyperplasias (Figure 2D). We further 
examined the macrophage phenotype in PN1a and PN1b 
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lesions by flow cytometry. PN1a lesions were dominated 
by TIE2+CD206+ macrophages, a subpopulation known 
for their pro-angiogenic and immunosuppressive functions 
[13–15], whereas PN1b lesions also contained a substantial 
number of TIE2-CD206- macrophages. Interestingly, the 
proportion of CD8+ cytotoxic lymphocytes was lower 
in PN1a as compared to PN1b lesions, consistent with a 
pro-tumorigenic, immunosuppressive microenvironment 
(Supplementary Figure 1). These results indicate that 
recruited macrophages and other immune cells are 
differentially expressed in pre-invasive lesions with a high 
Figure 1: PN1a lesions progress to invasive cancer. PN tissue was transplanted into the cleared fat pads of 3 week old Balb/c mice 
and allowed to grow for 8 or 16 weeks. A. Representative whole mount preparations of carmine alum stained mammary glands. Scale bar = 
2 mm. B. Representative 60X images of H&E staining of PN1a and PN1b lesions at 8 or 16 weeks post-transplantation. Scale bar = 5 μm.
Oncotarget50734www.impactjournals.com/oncotarget
Figure 2: PN1a lesions have increased infiltrating macrophages as compared to PN1b lessions. A. Heat map depicting gene 
expression patterns that are altered in PN1a and PN1b lesions at 8 weeks post-transplantation. B. Heat map depicting selected immune cell-
associated genes that were significantly changed in PN1a lesions as compared to PN1b and p53-/- lesions. C. Graphical representation of 
gene ontology terms significantly increased in PN1a as compared to PN1b lesions. P-values were determined by a one-sided Fisher’s exact 
test. D. Top: Graph shows quantitation of the average number of F4/80+ cells per field of view (FOV) in p53-/- glands, PN1a and PN1b. For 
each lesion, a minimum of 5 FOV were captured under 40X and F4/80+ cells were counted from 4 lesions (4 mice) for each group. Bottom: 
Representative 60X images of F4/80 staining in PN1a and PN1b lesions at 8 weeks post-transplantation, and p53-/- mammary glands 8 
weeks of age. A no primary antibody control from normal wildtype mammary glands is depicted. Scale bar = 20 μm. *p<0.05.
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tumor-forming potential as compared to lesions that lack 
invasive potential.
PN1a-associated macrophages exhibit a tumor-
promoting phenotype
Macrophages exhibit an enormous amount of 
plasticity and can have anti-tumor/pro-inflammatory 
properties or anti-inflammatory/tumor-promoting 
activities depending on local microenvironmental cues. 
Since PN1b lesions contain few recruited macrophages, 
the remainder of the study focused on characterizing 
macrophage activity in PN1a lesions exclusively. Flow 
cytometry was performed on PN1a lesions at various 
stages of progression to define the macrophage subtype. 
The percentage of CD45+F480+CD11b+ macrophages 
increased as PN1a lesions progressed to palpable 
tumors, suggesting that they may have tumor-promoting 
capabilities (Figure 3A). After gating on CD45+CD11b+ 
subpopulations, we assessed the cell surface expression 
Figure 3: Macrophage populations in early stage PN1a lesions express a mixture of pro- and anti-tumorigenic markers. 
Cells were isolated from PN1a lesions at different stages of progression and analyzed by flow cytometry. For all dot plots, live cells were 
selected by gating on SYTOX red- cells, and epithelial cells were excluded by gating on CD45+ cells. A. Dot plots show the numbers of 
F4/80+CD11b+ macrophages at different stages of PN1a progression. For B-D, CD11b+ subpopulations were first selected and further 
analyzed for the expression of B. CD206 and F4/80, C. CD204 and F4/80 and D. MHCII and F4/80. A minimum of 3 lesions (3 mice) were 
analyzed for each time point.
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of the pro-inflammatory macrophage marker, MHCII, 
and two anti-inflammatory macrophage markers, CD204 
and CD206, on F4/80+ cells. We observed that CD206 
expression peaked at 16 weeks post-transplantation, but 
decreased in palpable tumors (Figure 3B). In contrast, 
CD204 expression was low in macrophages in early stage 
lesions and increased in tumors (Figure 3C). Finally, the 
percentage of MHCIIHI macrophages was higher in early 
stage lesions, whereas tumors had a higher percentage of 
MHCIILO macrophages, consistent with CD206 expression 
(Figure 3D). This is concordant with previous studies that 
showed that MHCIIHI macrophages are increased in early 
stages of tumorigenesis where they function to recruit 
other immune cell populations through the production of 
chemokines such as CCL5, CCL22, and CCL17, and to 
suppress T-cell proliferation [16]. Together, these results 
suggest that infiltrating macrophages are dynamic as early 
stage lesions progress to invasive cancer, and express a 
spectrum of both pro- and anti-inflammatory markers.
To determine whether PN1a cells induce macrophage 
polarization toward a pro-tumor subtype, we exposed the 
macrophage cell line RAW 264.7 or bone marrow-derived 
macrophages (BMDMs) to growth media collected from 
PN1a cells (PN1a conditioned media), or growth media 
that was cultured in the absence of PN1a cells (control 
media). After 2 hours of exposure, RNA was isolated from 
RAW 264.7 cells or BMDMs and various genes were 
analyzed by qPCR (Figure 4). Several tumor-promoting 
markers were significantly increased in macrophages 
cultured with PN1a conditioned media as compared to 
Figure 4: PN1a cells polarize macrophages to a tumor-promoting phenotype. BMDMs and RAW 264.7 cells were cultured in 
the presence of PN1a conditioned media (CM) or control media. After 2 hours, cells were collected and qPCR was performed using primers 
to Arg1, Il10, Vegfa, Tgfb, Gas6, Il12p40, Nos2, Il6, and Tnfa. Values were normalized to GAPDH or 18S. Values shown are mean and SD 
(n=3) from one representative experiment. *p<0.05, **p<0.01,***p<0.001.
Oncotarget50737www.impactjournals.com/oncotarget
macrophages exposed to control media. Specifically, 
Arg1, Vegfa, Tgfb and Gas6 were induced in macrophages 
exposed to PN1a conditioned media. The pro-inflammatory 
genes Il12p40 and Nos2 (the gene that encodes the enzyme 
iNOS) were not significantly altered in PN1a-educated 
BMDMs, although Il12 was induced in RAW 264.7 cells. 
Il10, which has been shown to be immunosuppressive, was 
significantly increased in PN1a-educated macrophages. 
Interestingly, Il6 and Tnfa, which can be both pro-
inflammatory and tumor-promoting, were significantly 
upregulated in macrophages exposed to conditioned 
media as compared to control media (Figure 4). These 
results suggest that PN1a cells secrete factors that polarize 
macrophages toward a tumor-promoting phenotype, and 
that PN1a-associated macrophages represent a unique 
subpopulation of macrophages.
To test whether PN1a-associated macrophages 
have functional tumorigenic activity, we utilized a 3-D 
heterotypic culture system. Epithelial cells were isolated 
from PN1a lesions and cultured in Matrigel as previously 
described, in which normal mammary epithelial cells 
form polarized acini with empty lumens and an intact 
myoepithelium [17]. After 3 days of culture, BMDMs 
differentiated with L-929 conditioned media, were stained 
with a fluorescent dye and added to the cultures. After 13 
days of culture, PN1a cells in the absence of BMDMs 
formed uniformly round structures with filled lumens, 
reminiscent of simple ductal hyperplasia observed in vivo 
(Figure 5A, 5C). Staining with antibodies that mark the 
basal myoepithelium [cytokeratin (CK) 14 and integrin 
α6] and the luminal epithelium (CK18) revealed that 
PN1a cells alone formed an intact basal myoepithelium 
surrounding hyperplastic luminal cells (Figure 5C). In 
contrast, co-culture with BMDMs induced a tumor-
like phenotype characterized by irregular, disorganized 
structures and a disrupted basal cell layer. CK14+ cells 
were found throughout the co-cultured structures and 
integrin α6 was not uniformly expressed at the basal 
surface, further supporting a malignant phenotype. 
Quantification of non-malignant and tumor-like structures 
showed a significant increase in tumor-like PN1a acini in 
co-cultured cells as compared to PN1a alone (Figure 5B). 
Notably, BMDMs were recruited to the PN1a cells, 
suggesting that PN1a cells secrete chemokines that attract 
the BMDMs. Collectively, these results indicate that 
PN1a cells recruit and polarize macrophages to a tumor-
promoting phenotype.
Macrophage depletion delays progression to 
invasive cancer
To test whether macrophages have tumor-
promoting activity in vivo, macrophages were depleted 
in PN1a-bearing mice using clodronate liposomes. Equal 
numbers of PN1a cells were transplanted into the cleared 
fat pads of Balb/c mice and allowed to grow for 2 weeks. 
Then, macrophages were depleted by i.v. administration 
of clodronate liposomes every 3 days for an additional 
4 weeks. Flow cytometry showed a ~2 fold depletion 
of macrophages in clodronate liposome-treated animals 
in both the bone marrow (Supplementary Figure 2A) 
and in PN1a lesions (Figure 6A) as compared to saline-
treated animals, which is consistent with previous reports 
[18]. Immunostaining verified that macrophages were 
significantly depleted in areas adjacent to the lesions 
(Supplementary Figure 2D), and carmine-stained whole 
mount analysis showed that there was no significant 
difference in the percent of fat pad filled between saline- 
and clodronate-treated PN1a lesions (Supplementary 
Figure 2B), indicating that macrophage depletion did 
not effect the outgrowth potential of PN1a lesions. To 
address whether macrophages are required for early stage 
progression, the consequences of macrophage depletion 
was first addressed by determining histological grade of 
the pre-invasive lesions, as depicted in Supplementary 
Figure 2B. While 80% of the control lesions were 
classified as Grade 3, the majority of the macrophage-
depleted lesions were Grade 1/2, suggesting a significant 
delay in early progression (Figure 6B). The integrity 
of the basement membrane surrounding the PN1a 
epithelium was examined by immunostaining for the 
basement membrane protein laminin. Our data show that 
there was a significant increase in the number of lesions 
containing an intact basement membrane in macrophage-
depleted lesions as compared to macrophage-containing 
lesions (Figure 6C, 6F). In support, the number of 
proliferating cells was significantly decreased in 
macrophage-depleted lesions as compared to controls 
(Figure 6D, 6G). Finally, immunostaining using 
antibodies to CK14 and CK8 (luminal) showed a 
significant decrease in basal cells in clodronate liposome-
treated animals as compared to control mice, consistent 
with well-differentiated, low grade lesions (Figure 6E, 
6H). These results suggest that macrophage depletion 
delays the progression of pre-invasive lesions during the 
early stages of tumorigenesis.
Next, we asked whether macrophages were required 
for primary tumor formation. For these experiments, 
clodronate liposomes were administered every 3 days 
for 9 weeks (11 weeks post-transplantation), to allow 
for palpable tumor formation. Mammary tumors began 
to form as early as 7 weeks post-transplantation in both 
groups, however by 11 weeks, there was a significant 
reduction in palpable tumors in macrophage-depleted 
mice as compared to saline-treated animals. Furthermore, 
there was a significant decrease in tumor volume at 11 
weeks post-transplantation in macrophage-depleted mice 
as compared to control mice (Figure 7). Collectively, these 
results suggest that macrophages in early stage lesions are 
tumor-promoting and that depletion of macrophages in 
pre-invasive lesions significantly delays primary tumor 
formation.
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DISCUSSION
Early mammary lesions such as ADH and DCIS 
confer an increased relative risk for the development of 
breast cancer later in life [19]. Currently, the mechanisms 
that mediate the transition from pre-invasive lesions 
to invasive breast cancer are largely unknown. In this 
study, we utilized a unique transplantable model of early 
progression to identify factors driving the progression of 
premalignant mammary lesions. Gene profiling showed 
increased expression of several inflammatory chemokines 
and macrophage markers in PN1a lesions, which have 
a high tumor-forming potential, as compared to PN1b 
lesions, which rarely progress to tumors (Figure 2). 
Immunohistochemistry and flow cytometry showed that 
macrophages were recruited to ductal hyperplasias in 
PN1a lesions where they expressed cell surface markers 
characteristic of a tumor-promoting phenotype (Figure 2-3, 
Figure 5: Macrophages induce a malignant phenotype in PN1a cells grown in 3D culture. PN1a cells were co-cultured 
with BMDMs on Matrigel for 10 days. A. Representative phase-contrast images of PN1a acini alone (top) or after 10 days of co-culture 
with PKH26-labelled BMDMs (red) (bottom). Scale bar = 50 μm. B. Quantification of the number of tumor-like or non-malignant acini. 
Approximately 30 acini per group were examined for each experiment from 3 independent experiments. Error bars represent SD, and 
p-value was determined using a 2×2 contingency table and Chi-squared analysis (p<0.0001). C. (Left) Representative confocal images of 
acini immunostained with antibodies against CK-18 (green), CK-14 (purple), and nuclei were counterstained with DAPI (blue). Scale bar 
= 25 μm. (Right) Representative confocal images of structures immunostained with antibodies against α6-integrin (red), and nuclei were 
counterstained with DAPI (blue). Scale bars = 25 μm.
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Figure 6: Macrophage depletion using clodronate liposomes impairs the progression of PN1a lesions. A. Dot plot depicts 
that the number of CD45+CD11b+F4/80+ cells is decreased in PN1a lesions in clodronate liposome-treated mice as compared to saline-
treated. B. H&E analysis and quantification of histological grade of saline- and clodronate liposome-treated lesions. Values shown are the 
number of lesions classified for each histological grade, and a one-way ANOVA with Tukey post-hoc test was used to determine significant 
differences in grade (p< 0.05). C-E. Representative images of immunostaining of early stage PN1a lesions from saline- or clodronate-
treated mice using antibodies to C. pan-cytokeratin (PanCK, green) and laminin (red), showing intact or fragmented (white arrow) basement 
membranes, D. PanCK (green) and Ki67 (red), E. CK8 (green) and CK14 (red). F. Quantification of the integrity of the basement membrane 
as defined by intact, fragmented or negative. A minimum of 5 FOVs were counted for each lesion, and a minimum of 10 lesions (6 mice) 
were analyzed for each treatment group (n=10). G. Graph depicts the percentage of Ki67+ proliferating cells, calculated by counting 
total epithelial cell number by co-staining with PanCK. A minimum of 6 FOVs were counted per each lesion, and a minimum of 6 mice 
(9 lesions) were counted for each treatment group. H. Quantification of CK8 and CK14 staining. Ten FOV were counted for each lesion 
and a minimum of 10 lesions (6 mice) were counted for each group. Values are shown as the mean + SD. *p<0.05, **p<0.01, ***p<0.001. 
Scale bars = 20 μm.
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Supplementary Figure 1). In support, macrophages were 
recruited to PN1a acini in a 3-D co-culture system, where 
they induced a malignant phenotype (Figure 5). Finally, 
depletion of macrophages in vivo significantly delayed 
the progression of PN1a lesions to palpable tumors, 
suggesting a critical role for macrophages in early 
progression.
Tumor-associated macrophages in established 
tumors have been shown to promote breast cancer cell 
invasion, angiogenesis and metastasis [3, 20]. However, 
their function in early stage lesions has been debated. In 
the polyoma middle T antigen mouse model of mammary 
tumorigenesis (MMTV-PyMT), genetic ablation of 
Csf1 - a cytokine required for monocyte to macrophage 
differentiation – resulted in the attenuation of tumor 
metastasis and a reduction in multiple foci on the distal 
duct; however, the growth rate and incidence of primary 
tumors remained unchanged, suggesting that macrophages 
do not mediate tumor formation [21]. This data stands 
in contrast to a growing body of literature suggesting 
that macrophages at the pre-invasive stage have tumor-
promoting activities, including immunosuppression and 
promotion of cell invasion. Schwertfeger and colleagues 
showed that macrophages are recruited to mammary 
hyperplasias in response to FGFR activation, where they 
promote tumor cell migration and invasion in a CXCR2-
dependent manner [22, 23]. In a model of ulcerative colitis-
induced carcinogenesis, recruited macrophages were 
shown to have tumor-promoting function and to express 
numerous pro- and anti-inflammatory cytokines [24]. 
Likewise, our data suggests that recruited macrophages in 
ductal hyperplasias exert pro-tumorigenic activities that 
promote primary tumor formation. This model is highly 
relevant to human premalignancy as mutations in p53 
occur in some cases of ADH as well as 20-40% cases of 
DCIS [25]. Furthermore, p53-null pre-invasive lesions 
Figure 7: Macrophage depletion using clodronate liposomes impairs PN1a tumor formation in vivo. PN1a-bearing mice 
were administered clodronate liposomes (or saline control) every 3 days for 9 weeks (11 weeks post-transplantation), to allow for palpable 
tumor formation. A. Kaplan-Meier curve showing the number of fat pads with palpable masses at 0-11 weeks post-transplantation. The 
log rank test was used for statistical analysis (p=0.0456), and 20 lesions (10 mice) were included for each group. B. Scatter plots show 
quantification of tumor volume (mm3) at 11 weeks post-transplantation for saline-treated (18 lesions/tumors, 10 mice) or clodronate 
liposome-treated (12 lesions/tumors, 11 mice) *p<0.05.
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recapitulate the intra-tumoral heterogeneity displayed in 
human disease [11]. Macrophage activity during tumor 
initiation and early stage progression may depend on 
lesion histopathology, as MRI studies have shown that 
the infiltration of CD68+ cells is strongly associated with 
high grade comedo DCIS lesions [26]. Moreover, gene 
expression analysis of patients with DCIS demonstrated 
that a macrophage response signature is associated with 
high grade, ER/PR-negative DCIS, and that this signature 
is conserved during progression to invasive cancer [27]. 
Thus, the discordant findings on the role of macrophages 
in early stage mammary lesions may be a reflection of 
tumor heterogeneity, subtype specificity, or inherent 
differences of mouse models.
Once infiltrated into the tumor microenvironment, 
macrophages differentiate and respond to local cues to 
exert a variety of activities, including immunosuppression, 
angiogenesis, metastasis, tumor cell survival, migration 
and invasion [4]. Our in vitro data shows that PN1a-
secreted factors can induce macrophages to express 
a unique set of cytokines, including Arg1 and Tgfb 
(Figure 4), which have been shown to suppress tumor cell 
proliferation and CD8+ T-cell activity [28]. Interestingly, 
Il6 and Tnf were also induced. While these cytokines have 
classic roles in inflammation, they have more recently 
been shown to promote angiogenesis, metastasis and stem 
cell self-renewal [4, 29]. Finally, the pro-inflammatory 
cytokine Gas6 was induced (Figure 4), which has been 
shown to promote tumor cell survival and invasion 
[30]. These results suggest that PN1a pre-invasive cells 
differentiate macrophages toward a pro-tumorigenic 
phenotype. In support of this notion, others have shown 
that exposure of CD14+ peripheral blood mononuclear 
cells to breast cancer cell line-secreted factors increases 
their expression of the scavenger receptor CD163 and 
the OX-2 membrane glycoprotein, CD200R, while 
concomitantly decreasing their expression of the T-cell 
co-stimulatory molecule, CD86 [31]. Our flow cytometry 
analysis of macrophages in 8 and 16 week PN1a lesions 
showed high expression of the scavenger receptor, 
CD206, and MHCII as compared to macrophages in 
PN1a tumors, which had higher expression of the mannose 
receptor CD204 and were MHCIILO. This increase in 
MHCIILO macrophages in PN1a tumors is not surprising 
as MHCIILO macrophages have been associated with a 
hypoxic tumor microenvironment in breast, lung, and 
ovarian mouse tumor models [16, 28, 32]. In contrast, 
MHCIIHI macrophages have been shown to be associated 
with normoxic regions, exhibit a pro-inflammatory, 
anti-tumor phenotype, and have iNOS-dependent T-cell 
suppressor activity [16]. The expression of CD206+ and 
MHCIIHI populations in PN1a lesions suggest that these 
macrophages may exert both pro-tumor and anti-tumor 
functions.
In the developing mammary gland, macrophages 
are required for normal branching morphogenesis, ductal 
elongation, and the repopulation ability of mammary stem 
cells [33, 34]. Emerging evidence indicates that tumor-
promoting macrophages support cancer stem cell renewal, 
maintenance, and migratory capacity through the secretion 
of numerous factors including IL-6 and TNFα. Although 
it is unknown how the increase in macrophage infiltration 
may effect stem cell populations in PN1a lesions, the 
increased secretion of IL-6 and TNFα may support cancer 
stem cell function in PN1a lesions, which could contribute 
to the enhanced tumor-forming potential of PN1a lesions 
as compared to PN1b lesions. Further studies are required 
to address this mechanism.
Macrophages are highly plastic, and their 
phenotype can change in response to a variety of cues 
from their microenvironment. For instance, tumor and 
T-regulatory cell-derived IL-10 can skew macrophages 
toward an anti-inflammatory phenotype characterized 
by activation of STAT3 and increased expression of 
CD163, CCL18, and SOCS3. In addition, the cytokine, 
TNFα, along with IFN-γ induces macrophage expression 
of the immune-inhibitory receptor, PD-L1, leading to 
suppressed T-cell proliferation and cytokine production 
[35, 36]. Although it is unclear which PN1a-derived 
factors are driving this change in polarization, our 
microarray showed that prostaglandin was increased 
in PN1a lesions, which has previously been shown 
to be a tumor-derived factor capable of polarizing 
macrophages toward a tumor-promoting phenotype [37]. 
We also found increased expression of the macrophage 
chemotactic proteins, CCL2 and CSF-1. Both of these 
genes have been correlated with poor prognosis in breast 
cancer patients [38–40]. Moreover, several studies have 
shown a positive correlation between the number of 
infiltrating macrophages in invasive ductal carcinoma 
and the expression of CCL2, CSF-1, and CCL5 [41, 
42]. However, in vivo, the relative contribution of PN1a 
cell-derived factors toward macrophage polarization is 
likely more complex, as the presence of other immune 
cells such as B lymphocytes and T-regulatory cells may 
influence macrophage recruitment and polarization.
Over the last decade, considerable progress has 
been made characterizing tumor-associated macrophages 
in breast cancer. As a result, there are currently several 
anti-macrophage therapeutic strategies that have been 
developed and are currently in clinical trials for the 
treatment of metastatic breast cancer (clinicaltrials.
gov). These include blocking macrophages by inhibiting 
CSF-1/CSF1R signaling, as well as disrupting cytokines/
chemokines that recruit and polarize macrophages to a pro-
tumor phenotype. Our studies suggest that preferentially 
targeting macrophages and/or disrupting macrophage 
polarization may also be beneficial in patients with early 
stage lesions. However, further studies are required 
to understand the mechanisms that drive macrophage 
recruitment, polarization and function in pre-invasive 
mammary lesions.
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MATERIALS AND METHODS
Mice and cell lines
Mice were maintained in a pathogen-free facility 
in accordance with the NIH Guide for the Care and Use 
of Experimental Animals with approval from the Tulane 
School of Medicine Institutional Animal Care and Use 
Committee. Balb/c mice were obtained from Envigo, and 
Trp53-/- mice (Balb/c) have been described [43]. RAW 
264.7 cells (ATCC) were maintained in DMEM containing 
10% fetal bovine serum (FBS) (Life Technologies) and 1% 
penicillin-streptomycin (Life Technologies). L929 cells 
were a kind gift from Dr. Kathryn L. Schwertfeger’s lab 
(University of Minnesota) and L929 conditioned media 
was prepared from them as previously described [44]. All 
cell lines used in these studies were authenticated by STR 
Profiling (DDC Medical). All tissue culture materials used 
for the isolation and analysis of macrophages were made 
of polypropylene.
Transplantation, whole mount analysis, and 
immunostaining of mammary glands
PN1a and PN1b lesions were derived from 
Trp53-/- mice (Balb/c) as previously described [11]. For 
maintaining and expanding tissue, contralateral mammary 
glands containing PN1a or PN1b lesions after 8 weeks 
of outgrowth were minced into 1 mm fractions with a 
scalpel and re-transplanted into the cleared fat pads (#4 
contralateral glands) of 3 week old female Balb/c mice 
(weight 10-13 g) as previously described [45]. For whole 
mount analysis, mammary glands were fixed in cold 4% 
paraformaldehyde (Thermo Fisher Scientific) for 2 hours 
and stained with carmine alum (Sigma Aldrich) overnight. 
The next day, glands were dehydrated in a series of 
ethanols and placed in xylene before imaging on a Leica 
M165 FC stereoscope (Leica Biosystems). Mammary 
glands were then embedded in paraffin and sectioned, 
and sections were deparaffinized and rehydrated before 
staining with hematoxylin and eosin (H&E).
Immunostaining was performed as previously 
described [46] with the following modifications: 
immunohistochemistry with F4/80 was performed in 
absence of antigen retrieval, endogenous peroxidases were 
blocked by incubating sections in a solution containing 
3% hydrogen peroxide and methanol, and M.O.M. 
blocking reagent (Vector Labs) was used for mouse 
monoclonal antibodies. Primary antibody incubations 
were performed according to the manufacturer’s 
instructions (Supplementary Table 1). For each mammary 
gland (10 mammary glands per antibody), 8-10 random 
fields of view (FOV) were captured using a Nikon Eclipse 
Ci microscope (Nikon Instruments) at 40X magnification 
unless otherwise specified, and positive cells were counted 
using the NIS-Elements Basic research Software (Nikon 
Instruments). For quantification of macrophages, F4/80+ 
cells were expressed as the average number of positive 
cells per FOV. For quantification of Ki67, the number 
of positive cells was calculated as a percentage of total 
epithelial cells using panCK co-staining as a marker of 
epithelium. Laminin expression was expressed as the 
percentage of lesions counted and lesions were categorized 
as having an intact, discontinuous, or negative basement 
membrane status based on previous studies [47].
Gene expression profiling
Mammary glands from PN1a (n=5) or PN1b (n=6) 
lesions at 8 weeks post-transplantation, or p53-/- mice 
(n=3) at 10 weeks of age were removed and homogenized 
in TRIzol reagent (Life Technologies) to fully lyse 
the tissue. Total RNA was isolated according to the 
manufacturer’s instructions, followed by Qiagen RNeasy 
column purification (Qiagen). cRNA was synthesized and 
hybridized onto Affymetrix MG_U74Av2 chips using 
recommended procedures for synthesis, hybridization, 
washing, and staining with streptavidin-phycoerythrin. 
CEL files were processed using dChip (using PM-MM 
model and quantile normalization). Differences were 
defined between PN1a and PN1b samples using a two-
sided t-test (on log-transformed values) and fold change. 
Differences between PN1a and p53-/- samples, and 
PN1b and p53-/- samples, as well as a complete list of 
the top differential genes are included in Supplementary 
Table 2. Gene Ontology term enrichment was determined 
using the SigTerms tool [48]. Array data were deposited 
in the Gene Expression Omnibus (accession number 
GSE84828).
Flow cytometry
For analysis of immune cells, PN1a glands were 
dissected from Balb/c mice, minced and digested for 20 
minutes with shaking in a DMEM/F12 (Life Technologies) 
media containing 1 mg/ml of collagenase A (Roche), 25 
μg/ml of DNAse I (Roche), and 1% antibiotic-antimycotic 
(Life Technologies). Lymph nodes were removed from 
all mammary glands prior to mincing. Digestion was 
neutralized by adding DMEM/F12 (Life Technologies), 
supplemented with 10% FBS (Life Technologies), and 
cells were filtered four times through a 70 μm strainer (BD 
Bioscience). Cells were then incubated at 4°C with 1 μg/
million cells of CD16/CD32 Fc block (BD Bioscience) 
for 10 minutes and incubated on ice for 30 minutes 
with fluorophore conjugated anti-mouse antibodies as 
indicated in Supplementary Table 1. Subsequently, cells 
were washed twice with Hank’s balanced salt solution 
(HBSS) (Life Technologies) containing 2% FBS (Life 
Technologies), filtered through a 35 μm cell strainer (BD 
Bioscience), and stained with 5 nM SYTOX red or 7AAD 
(Life Technologies). Flow cytometry was performed using 
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a LSRII or FACSAria IIu cell sorter (BD Biosciences) and 
analyzed with FlowJo v10.1 (Tree Star, Inc).
Epithelial cell isolation from PN1a lesions
To isolate epithelial cells from PN1a lesions, 
mammary glands containing 8 week outgrowths of 
PN1a lesions were minced into 1 mm fractions using a 
scalpel and digested for 1 hour with shaking in DMEM/
F12 (Life Technologies) media containing 1X antibiotic-
antimycotic (Life Technologies), 2 mg/ml of collagenase 
A (Roche), and 25 ug/ml of DNAse I (Roche). Then, the 
cells were washed with DMEM/F12 (Life Technologies) 
containing 5% FBS (Life Technologies) and enriched for 
epithelial organoids by a series of four 3 second pulses at 
450 x g [49]. Enriched organoids were trypsinized (0.05% 
trypsin) for 20 minutes, passed through a 70 μm filter (BD 
Bioscience), and washed with PBS (Life Technologies). 
Subsequently, PN1a cells were centrifuged at 600 x g for 
5 minutes, trypsinized for 5 minutes, and passed through 
a 70 μm filter (BD Bioscience). The resulting enriched 
population was centrifuged for 10 minutes at 600 x g and 
resuspended in DMEM/F12 media containing 5% FBS 
(Life Technologies), 1% antibiotic-antimycotic (Life 
Technologies), 5 μg/ml of insulin (Sigma Aldrich), and 5 
ng/ml of epidermal growth factor (EGF) (Millipore) and 
prepared for experiments.
Preparation of bone marrow-derived 
macrophages
Bone marrow was obtained from the femur and 
tibia of C57BL/6 mice as described [50]. Cells were 
cultured in a 10 cm petri dish for one week in DMEM 
(Life Technologies) supplemented with 10% FBS (Life 
Technologies), 1% penicillin and streptomycin (Life 
Technologies), and 20% L929 conditioned media. After 7 
days of culture, BMDMs were enriched for F4/80-positive 
cells using the Magnisort F4/80 positive selection kit 
(eBioscience) according to the manufacturers instructions.
Two-dimensional co-culture
PN1a cells were isolated from mammary glands 
containing 8 week old outgrowths as described above. 
One million cells were seeded in a 6 well plate in 
DMEM/F12 containing 5% FBS (Life Technologies), 1% 
antibiotic-antimycotic (Life Technologies), 5 μg/ml of 
insulin (Sigma Aldrich), and 5 ng/ml of EGF (Millipore), 
and incubated at 37°C/5% CO
2
. For control media, 
DMEM/F12 containing 5% FBS (Life Technologies), 1% 
antibiotic-antimycotic (Life Technologies) was added to 
a 6 well plate and incubated at 37°C/5% CO
2
. After 72 
hours, conditioned or control media was collected and 
added to BMDMs or RAW 264.7 cells that had been serum 
starved overnight. After 2 hours, cells were collected in 
TRIzol (Life Technologies) for gene expression analysis.
Quantitative RT-PCR
Total RNA was extracted from RAW 264.7 cells 
or primary BMDMs using TRIzol and DNA-free DNA 
Removal Kit (Life Technologies) according to the 
manufacturer’s instructions. cDNA was prepared using 
the iScript cDNA Synthesis Kit (Biorad) and qPCR was 
performed using SYBR green methodology on a CFX96 
Touch Real-Time Detection System (Biorad). The primer 
sequences are listed in Supplementary Table 3, and the 
relative gene expression changes were determined using 
the 2-ΔΔCt method, where GAPDH (RAW 264.7) or 18S 
(BMDMs) served as the internal control. For each gene, 
3 (RAW 264.7 cells) or 4 (BMDMs) biological replicates 
were analyzed.
Three-dimensional co-culture
Epithelial cells were isolated from PN1a lesions 
at 8 weeks post-transplantation as described above 
and further enriched using EasySep Mouse Epithelial 
Cell Enrichment Kit (STEMCELL Technologies). Ten 
thousand PN1a cells were seeded on growth factor-
reduced Matrigel® (BD Bioscience) in a Nunc 8 well 
chamber system (Thermo Fisher Scientific) as described 
previously [17]. After 3 days, BMDMs that had been 
isolated as described above were labeled with PKH26 
(Sigma Aldrich) and added to the culture. After 10 days 
of co-culture, the structures were imaged under a 40X 
objective using an Evos FL microscope (Thermo Fisher 
Scientific). Subsequently, the slides were fixed with 
2% paraformaldehyde, permeablized with 0.5% Triton 
X-100 (Thermo Fisher Scientific), and washed with PBS 
containing 100 mM glycine (Thermo Fisher Scientific). 
Afterwards, the slides were blocked with PBS containing 
10% goat serum (Life Technologies), 0.1% BSA (Sigma 
Aldrich,), 0.2% Triton-X 100 (Thermo Fisher Scientific), 
and 0.05% Tween-20 (Sigma Aldrich) for 1 hour, and 
stained with primary antibodies listed in Supplementary 
Table 1 overnight at room temperature. The following 
day, slides were washed with PBS containing 10% goat 
serum (Life Technologies), 0.1% BSA (Sigma Aldrich), 
0.2% Triton-X 100 (Thermo Fisher Scientific), and 0.05% 
Tween-20 (Sigma Aldrich) and stained with anti-mouse 
or anti-rabbit secondary antibodies conjugated to Alexa 
Fluor dyes for one hour. Afterwards, slides were wash 
and mounted withVectashield Mounting medium with 
4’,6-Diamidino-2-phenylindole (DAPI) (Vector Labs). 
Confocal images were acquired under a 60X object using a 
Nikon A1plus confocal microscope with PMT and GaASP 
detectors.
Macrophage depletion
PN1a cells were isolated from mammary glands 
containing PN1a lesions 8 weeks post-transplantation 
as described above. Viable cells were counted on a 
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hemacytometer using trypan blue exclusion dye and 
resuspended at a concentration of 1,000 cells/10 μl in a 
1:1 solution of PBS and growth factor-reduced Matrigel® 
(BD Biosciences). Ten microliters of cells were injected 
into contralateral cleared fad pads of 3 week old syngeneic 
mice using a 26 gauge needle and a 50 μl Hamilton 
glass syringe (Hamilton Company). After two weeks, 
mice were randomly distributed into groups and began 
intravenous injection (tail vein) of 100 μl (5 mg) per 
10 g of body weight of clodronate-liposomes (clodLIP 
B.V.) or an equal volume of saline every 3 days. Long-
term intravenous administration of clodronate-liposomes 
has been previously shown to deplete all macrophage 
subsets in the liver, spleen, and bone marrow as well as 
precursor blood monocytes in circulation [51]. Different 
cohorts were treated for the indicated times depending 
on the experiment. For tumor latency studies, mice were 
palpated and tumors size was measured with calipers 
every other day. Tumor volume was calculated at time 
of sacrifice (11 weeks) based on the formula (LxW2)/2. 
One mouse in the saline group was sacrificed early due 
to a tumor volume greater than 10% of body weight, and 
two mice in the clodronate group were sacrificed early do 
injection site related illness. All 3 mice were censored in 
the Kaplan-Meier plot, and excluded from tumor volume 
quantification. Body mass was measured at week 11 to 
verify health status of all mice included in tumor latency 
studies.
Statistical analysis
All tests were performed using GraphPad 
Prism 5. The significance of fold changes for qPCR 
and immunostaining results was calculated using an 
unpaired t-test. Data was verified as Gaussian using the 
D’Agostino-Pearson Omnibus. For the quantification 
of histological grade, significance was calculated using 
one way ANOVA with Tukey post-hoc test. For tumor 
latency experiments, time was counted from the day 
of PN1a transplantation until the time of sacrifice. The 
significance was calculated using the log rank test. 
For 3-D co-culture experiments, the number of non-
malignant and tumor-like acini were counted in each 
well and the significance was calculated using a 2×2 
contigency and Chi-squared analysis.
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